Literature DB >> 22065722

A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment.

Hagen Kulbe1, Probir Chakravarty, D Andrew Leinster, Kellie A Charles, Joseph Kwong, Richard G Thompson, Jermaine I Coward, Tiziana Schioppa, Stephen C Robinson, William M Gallagher, Laura Galletta, Michael A Salako, John F Smyth, Thorsten Hagemann, Donal J Brennan, David D Bowtell, Frances R Balkwill.   

Abstract

Constitutive production of inflammatory cytokines is a characteristic of many human malignant cell lines; however, the in vitro and in vivo interdependence of these cytokines, and their significance to the human cancer microenvironment, are both poorly understood. Here, we describe for the first time how three key cytokine/chemokine mediators of cancer-related inflammation, TNF, CXCL12, and interleukin 6, are involved in an autocrine cytokine network, the "TNF network," in human ovarian cancer. We show that this network has paracrine actions on angiogenesis, infiltration of myeloid cells, and NOTCH signaling in both murine xenografts and human ovarian tumor biopsies. Neutralizing antibodies or siRNA to individual members of this TNF network reduced angiogenesis, myeloid cell infiltration, and experimental peritoneal ovarian tumor growth. The dependency of network genes on TNF was shown by their downregulation in tumor cells from patients with advanced ovarian cancer following the infusion of anti-TNF antibodies. Together, the findings define a network of inflammatory cytokine interactions that are crucial to tumor growth and validate this network as a key therapeutic target in ovarian cancer. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22065722      PMCID: PMC3252703          DOI: 10.1158/0008-5472.CAN-11-2178

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

1.  Rethinking ovarian cancer: recommendations for improving outcomes.

Authors:  Sebastian Vaughan; Jermaine I Coward; Robert C Bast; Andy Berchuck; Jonathan S Berek; James D Brenton; George Coukos; Christopher C Crum; Ronny Drapkin; Dariush Etemadmoghadam; Michael Friedlander; Hani Gabra; Stan B Kaye; Chris J Lord; Ernst Lengyel; Douglas A Levine; Iain A McNeish; Usha Menon; Gordon B Mills; Kenneth P Nephew; Amit M Oza; Anil K Sood; Euan A Stronach; Henning Walczak; David D Bowtell; Frances R Balkwill
Journal:  Nat Rev Cancer       Date:  2011-09-23       Impact factor: 60.716

Review 2.  EGF-ERBB signalling: towards the systems level.

Authors:  Ami Citri; Yosef Yarden
Journal:  Nat Rev Mol Cell Biol       Date:  2006-07       Impact factor: 94.444

3.  A system for stable expression of short interfering RNAs in mammalian cells.

Authors:  Thijn R Brummelkamp; René Bernards; Reuven Agami
Journal:  Science       Date:  2002-03-21       Impact factor: 47.728

4.  Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer.

Authors:  Srinivasan Madhusudan; Sethupathi R Muthuramalingam; Jeremy P Braybrooke; Susan Wilner; Kulwinder Kaur; Cheng Han; Susan Hoare; Frances Balkwill; Trivadi S Ganesan
Journal:  J Clin Oncol       Date:  2005-09-01       Impact factor: 44.544

Review 5.  The genesis and evolution of high-grade serous ovarian cancer.

Authors:  David D L Bowtell
Journal:  Nat Rev Cancer       Date:  2010-10-14       Impact factor: 60.716

6.  ARID1A mutations in endometriosis-associated ovarian carcinomas.

Authors:  Kimberly C Wiegand; Sohrab P Shah; Osama M Al-Agha; Yongjun Zhao; Kane Tse; Thomas Zeng; Janine Senz; Melissa K McConechy; Michael S Anglesio; Steve E Kalloger; Winnie Yang; Alireza Heravi-Moussavi; Ryan Giuliany; Christine Chow; John Fee; Abdalnasser Zayed; Leah Prentice; Nataliya Melnyk; Gulisa Turashvili; Allen D Delaney; Jason Madore; Stephen Yip; Andrew W McPherson; Gavin Ha; Lynda Bell; Sian Fereday; Angela Tam; Laura Galletta; Patricia N Tonin; Diane Provencher; Dianne Miller; Steven J M Jones; Richard A Moore; Gregg B Morin; Arusha Oloumi; Niki Boyd; Samuel A Aparicio; Ie-Ming Shih; Anne-Marie Mes-Masson; David D Bowtell; Martin Hirst; Blake Gilks; Marco A Marra; David G Huntsman
Journal:  N Engl J Med       Date:  2010-09-08       Impact factor: 91.245

7.  Jagged-1 and Notch3 juxtacrine loop regulates ovarian tumor growth and adhesion.

Authors:  Jung-Hye Choi; Joon T Park; Ben Davidson; Patrice J Morin; Ie-Ming Shih; Tian-Li Wang
Journal:  Cancer Res       Date:  2008-07-15       Impact factor: 12.701

8.  Expression and regulation of tumor necrosis factor alpha in normal and malignant ovarian epithelium.

Authors:  Peter W Szlosarek; Matthew J Grimshaw; Hagen Kulbe; Julia L Wilson; George D Wilbanks; Frances Burke; Frances R Balkwill
Journal:  Mol Cancer Ther       Date:  2006-02       Impact factor: 6.261

9.  Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer.

Authors:  Donal J Brennan; Jenny Brändstedt; Elton Rexhepaj; Michael Foley; Fredrik Pontén; Mathias Uhlén; William M Gallagher; Darran P O'Connor; Colm O'Herlihy; Karin Jirstrom
Journal:  BMC Cancer       Date:  2010-04-01       Impact factor: 4.430

10.  Integrated genomic analyses of ovarian carcinoma.

Authors: 
Journal:  Nature       Date:  2011-06-29       Impact factor: 49.962

View more
  95 in total

Review 1.  Lessons from rare tumors: hepatic lymphoepithelioma-like carcinomas.

Authors:  Antonio Solinas; Diego F Calvisi
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

2.  Many Roles of CCL20: Emphasis on Breast Cancer.

Authors:  Kingsley O Osuala; Bonnie F Sloane
Journal:  Postdoc J       Date:  2014-03

Review 3.  Targeted immune therapy of ovarian cancer.

Authors:  Keith L Knutson; Lavakumar Karyampudi; Purushottam Lamichhane; Claudia Preston
Journal:  Cancer Metastasis Rev       Date:  2015-03       Impact factor: 9.264

4.  Correction.

Authors: 
Journal:  Cancer Sci       Date:  2016-07       Impact factor: 6.716

Review 5.  The immune system in the pathogenesis of ovarian cancer.

Authors:  Bridget Charbonneau; Ellen L Goode; Kimberly R Kalli; Keith L Knutson; Melissa S Derycke
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

6.  Selective blockade of matrix metalloprotease-14 with a monoclonal antibody abrogates invasion, angiogenesis, and tumor growth in ovarian cancer.

Authors:  Rajani Kaimal; Raid Aljumaily; Sarah L Tressel; Rutika V Pradhan; Lidija Covic; Athan Kuliopulos; Corrine Zarwan; Young B Kim; Sheida Sharifi; Anika Agarwal
Journal:  Cancer Res       Date:  2013-02-19       Impact factor: 12.701

Review 7.  Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?

Authors:  Michael Hölzel; Anton Bovier; Thomas Tüting
Journal:  Nat Rev Cancer       Date:  2013-03-28       Impact factor: 60.716

8.  Effect of IL-6 and IL-8 on the expression of the complement activation inhibitors MAC-inhibitory protein and decay-accelerating factor in ovarian cancer A2780 cells.

Authors:  Lucyna Kapka-Skrzypczak; Sylwia Popek; Krzysztof Sawicki; Ewa Wolińska; Magdalena Czajka; Maciej Skrzypczak
Journal:  Oncol Lett       Date:  2016-06-28       Impact factor: 2.967

9.  TNF-α expression, risk factors, and inflammatory exposures in ovarian cancer: evidence for an inflammatory pathway of ovarian carcinogenesis?

Authors:  Mamta Gupta; Ana Babic; Andrew H Beck; Kathryn Terry
Journal:  Hum Pathol       Date:  2016-04-08       Impact factor: 3.466

10.  A prospective study of circulating C-reactive protein, interleukin-6, and tumor necrosis factor α receptor 2 levels and risk of ovarian cancer.

Authors:  Elizabeth M Poole; I-Min Lee; Paul M Ridker; Julie E Buring; Susan E Hankinson; Shelley S Tworoger
Journal:  Am J Epidemiol       Date:  2013-08-21       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.